Strategic partnership Leverage existing and recent partnerships with Pfizer, Chiesi, and Secarna to identify co-development or regional commercialization opportunities for new plant cell-based therapeutics, particularly in rare diseases and specialty markets that align with ProCellEx capabilities.

Global footprint Capitalize on multi-market approvals for taliglucerase alfa and ongoing international commercialization to pursue license deals or distributor arrangements in additional high-potential regions, including LATAM and Asia, leveraging Protalix's manufacturing platform.

Pipeline strength Target collaboration or out-licensing discussions around high-promise candidates such as pegunigalsidase alfa, alidornase alfa, PRX 115, and PRX 119 with pharmaceutical partners seeking novel biologics or niche therapies, reducing development risk through ProCellEx expertise.

Financial momentum With turning profitability and quarterly revenue growth, pursue strategic financings or milestone-based partnerships to fund pipeline advancement, manufacturing scale-ups, and potential expansion of production capacity via the ProCellEx platform.

Technology leverage Position Protalix as a platform-driven partner for biotech firms seeking plant cell-based expression solutions by offering co-development, contract manufacturing, and accelerated timelines to clinic, supported by cloud-enabled operations and global tech stack.